Related Experiment Video
Updated: Jul 17, 2026
Chemical Inactivation of the E3 Ubiquitin Ligase Cereblon by Pomalidomide-based Homo-PROTACs
Published on: May 15, 2019
Valproic acid induces non-apoptotic cell death mechanisms in multiple myeloma cell lines
Chantal Schwartz1, Valerie Palissot, Nassera Aouali
1Laboratoire d'Hémato-Cancérologie Expérimentale, CRP-Santé, 84 Val Fleuri, L-1526 Luxembourg.
Abstract:
Multiple myeloma (MM) is an incurable hematological disorder characterized by dysregulated proliferation of terminally differentiated plasma cells. Aberrant histone acetylation has been observed in the development of numerous malignancies. Histone deacetylase inhibitors such as valproic acid (VPA) are promising drugs for cancer therapy since they have been reported to have antiproliferative effects and to induce differentiation in carcinoma and leukemic cells. Considering the advantage of being already in clinical use for epilepsy treatment, valproic acid might be a promising therapeutic candidate drug in the management of multiple myeloma. In this study, we show that the short fatty acid VPA has a time and dose-dependent cytotoxic effect on the MM cell lines OPM2, RPMI and U266. The influence of VPA on cell cycle and apoptosis have been evaluated by flow cytometry. Our results show that the three cell lines are blocked in G0/G1 phase. The observed sensitivity to VPA can be partially explained by late apoptosis. Since caspase 3 is activated in all tested cell lines after VPA treatment, a caspase-dependent pathway seems to be involved but not activated by the classic apoptotic pathways. We have also studied another mechanism of cell death, the senescence-like phenotype, but did not find any evidence for its implication. Thus, treatment with VPA may imply other alternative cell death mechanisms.
Insights
Valproic acid (VPA) demonstrates cytotoxic effects on multiple myeloma cells by inducing cell cycle arrest and apoptosis. This suggests VPA as a potential therapeutic agent for managing multiple myeloma.
Area of Science:
- Oncology
- Hematology
- Pharmacology
Background:
- Multiple myeloma (MM) is an incurable plasma cell malignancy.
- Aberrant histone acetylation is implicated in cancer development.
- Histone deacetylase inhibitors show anti-cancer potential.
Purpose of the Study:
- To investigate the efficacy of valproic acid (VPA) as a potential therapeutic agent for multiple myeloma.
- To evaluate the effects of VPA on multiple myeloma cell lines.
Main Methods:
- Exposure of MM cell lines (OPM2, RPMI, U266) to VPA.
- Assessment of cell viability, cell cycle progression, and apoptosis via flow cytometry.
- Analysis of caspase activation and senescence-like phenotype.
Main Results:
- VPA exhibited a time- and dose-dependent cytotoxic effect on MM cell lines.
- VPA treatment resulted in G0/G1 cell cycle arrest.
- Late apoptosis and caspase 3 activation were observed, suggesting a caspase-dependent pathway.
Conclusions:
- Valproic acid shows promise as a therapeutic candidate for multiple myeloma management.
- VPA induces MM cell death through G0/G1 arrest and caspase-dependent apoptosis.
- Alternative cell death mechanisms may be involved in VPA's action.
Related Concept Videos
01:31The Intrinsic Apoptotic Pathway
01:30Overview of Cell Death
Cell death was observed in the early 19th century, but there was no experimental evidence to prove it. In 1842, Carl Vogt first discovered cell death in a metamorphic toad; however, it was not termed ‘cell death.’ Scientists discovered different cell death pathways only in the 20th century...
02:23Abnormal Proliferation
01:17The Extrinsic Apoptotic Pathway
01:30Apoptosis
01:18Autophagic Cell Death
Autophagy and Apoptosis
Autophagy can activate apoptosis. In normal conditions, the autophagy activating protein Beclin-1 and pro-apoptotic...